echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Toripalimab is a combination of chemotherapy to treat nasopharyngeal cancer, and China's State Drug Administration has approved its application for complementary new drugs

    Toripalimab is a combination of chemotherapy to treat nasopharyngeal cancer, and China's State Drug Administration has approved its application for complementary new drugs

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Nasopharyngeal cancer is a type of cancer that occurs in the nasopharyngeal cavity or upper throat.
    in some parts of the world, such as South-East Asia and Africa, more people suffer from the disease than in others, which were thought to be primarily dietary effects and are now tending to be genetically based on major influences.
    Chinese pharmaceutical company Junshi Bio recently announced that China's State Drug Administration (NMPA) has accepted a new supplemental drug application for the first-line treatment of relapsed or metastatic nasopharyngeal cancer with Toripalimab combined chemotherapy.
    approval is based on the latest results from the JUPITER-02 Study (NCT03581786), a randomized, double-blind, placebo-controlled Phase III study.
    results showed that toripalimab monoantigen/cisplatin first-line therapy significantly extended the patient's progressive survival (PFS) when treating patients with relapsed or metastatic nasopharyngeal cancer with monoantigen/cisplatin first-line therapy.
    previously, Toripalimab had been awarded the "Breakthrough Therapy Title" and "Orphan Drug Title" from the FDA for the treatment of nasopharyngeal cancer, and Junshi Bio would also submit a Biological Agent Licensing Application (BLA) in the United States.
    toripalimab could become the first Chinese anti-PD-1 monoclonal antibody to commercialize in overseas markets.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.